Valeant Turns From Buyer to Seller as Debt Repayments Loom

  • Embattled drugmaker seeks to unload only ‘non-core’ businesses
  • ‘It’s not so much ‘Can they get a sale?’ It’s at what price.’

Valeant Maintains Full-Year Guidance Despite Profit Miss

Over the last six years, Valeant Pharmaceuticals International Inc. piled up a mountain of debt building its business through more than 50 acquisitions. It now may have to sell some of those very same assets to help pay off almost $5 billion that will come due by or during 2018.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.